Upadacitinib Hemihydrate (Rinvoq)
AbbVie
Description
Rinvoq (upadacitinib) is a selective and reversible Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit cytokine or growth factor signals involved in a broad range of cellular processes including inflammatory responses, hematopoiesis, and immune surveillance. The JAK family of enzymes contains four members, JAK1, JAK2, JAK3 and TYK2 which work in pairs to phosphorylate and activate signal transducers and activators of transcription (STATs). This phosphorylation, in turn, modulates gene expression and cellular function. JAK1 is important in inflammatory cytokine signals while JAK2 is important for red blood cell maturation and JAK3 signals play a role in immune surveillance and lymphocyte function.
Indications
Moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy; active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs (may be used as monotherapy or in combination with methotrexate); moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy
Contraindications
Hypersensitivity to the active substance or to any of the excipients; active tuberculosis or active serious infections; severe hepatic impairment; pegnancy
Price
28× 15mg, £805.56; 28× 30mg, £1281.54; 28× 45mg, £2087.10
More on: Systemic eczema treatments